| 8001 | SLURP1 levels | GCST90470674 | 9.53e-03 |
| 8002 | Daytime nap | GCST011494 | 9.52e-03 |
| 8003 | Salad dressing liking | GCST90094822 | 9.52e-03 |
| 8004 | NUCB2/TXNDC5 ratio | GCST90315578 | 9.49e-03 |
| 8005 | CCL11/CCL7 ratio | GCST90313673 | 9.49e-03 |
| 8006 | FCER1A levels | GCST90469198 | 9.48e-03 |
| 8007 | FKBP1B/TGFB1 ratio | GCST90314836 | 9.46e-03 |
| 8008 | IL12A_IL12B/LAG3 ratio | GCST90315147 | 9.44e-03 |
| 8009 | HSPB1/QDPR ratio | GCST90315089 | 9.42e-03 |
| 8010 | CD59/PI3 ratio | GCST90313858 | 9.40e-03 |
| 8011 | Illness, injury, bereavement, stress in last 2 years - Financial difficulties | Mental health | UKBB00000338 | 9.40e-03 |
| 8012 | Sodium in urine | Urine assays | UKBB00000785 | 9.39e-03 |
| 8013 | Cholesteryl esters in very small VLDL (UKB data field 23520) | GCST90269617 | 9.37e-03 |
| 8014 | HMBS/UBAC1 ratio | GCST90315066 | 9.37e-03 |
| 8015 | Follicular cysts of skin and subcutaneous tissue | FING00000547 | 9.36e-03 |
| 8016 | Clinical LDL cholesterol levels (UKB data field 23404) | GCST90269501 | 9.36e-03 |
| 8017 | CSF2 levels | GCST90468884 | 9.34e-03 |
| 8018 | Cholesteryl Esters in VLDL | GCST90500205 | 9.33e-03 |
| 8019 | EBAG9/TBCB ratio | GCST90314567 | 9.33e-03 |
| 8020 | Principal component-derived dietary pattern 30 | GCST90133035 | 9.32e-03 |
| 8021 | CKAP4 levels | GCST90468758 | 9.31e-03 |
| 8022 | SIGLEC5 levels | GCST90470633 | 9.31e-03 |
| 8023 | MMP13 levels | GCST90469917 | 9.30e-03 |
| 8024 | Duration to complete alphanumeric path task (baseline) | GCST90565839 | 9.30e-03 |
| 8025 | Mean platelet volume during second trimester of pregnancy | GCST90302230 | 9.26e-03 |
| 8026 | Sleeplessness / insomnia | Sleep | UKBB00000778 | 9.24e-03 |
| 8027 | ESM1 levels | GCST90469153 | 9.24e-03 |
| 8028 | DTI TBSS L2 Anterior limb of internal capsule L | GCST90384493 | 9.22e-03 |
| 8029 | GP6/SEMA4D ratio | GCST90314971 | 9.21e-03 |
| 8030 | T1 FreeSurfer aseg MaskVol-to-eTIV | GCST90384192 | 9.19e-03 |
| 8031 | Serum 25-Hydroxyvitamin D levels | GCST90000614 | 9.15e-03 |
| 8032 | APOA levels | UKBB00000040 | 9.14e-03 |
| 8033 | Total lipids in small HDL | GCST90499456 | 9.12e-03 |
| 8034 | EDAR/TREML2 ratio | GCST90314592 | 9.10e-03 |
| 8035 | Renal failure (PheCode 585) | GCST90476118 | 9.05e-03 |
| 8036 | CSNK1G2 levels | GCST90240608 | 9.03e-03 |
| 8037 | Phospholipids to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23579) | GCST90269676 | 9.03e-03 |
| 8038 | Cholesterol to Total Lipids in Small VLDL percentage | GCST90499760 | 9.02e-03 |
| 8039 | KIAA2013 levels | GCST90469679 | 8.93e-03 |
| 8040 | Other enthesopathies | FING00001045 | 8.93e-03 |
| 8041 | AHSG levels | GCST90468263 | 8.92e-03 |
| 8042 | Postmenopausal breast cancer | GCST90428116 | 8.92e-03 |
| 8043 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 81) | GCST90320900 | 8.92e-03 |
| 8044 | CPB1/KIRREL2 ratio | GCST90314210 | 8.91e-03 |
| 8045 | Other diseases of urinary system | FING00001013 | 8.89e-03 |
| 8046 | Osteomyelitis | FING00000911 | 8.89e-03 |
| 8047 | PADI4 levels | GCST90470143 | 8.88e-03 |
| 8048 | IL2RA/NCR1 ratio | GCST90315161 | 8.88e-03 |
| 8049 | FCRL1/TREML2 ratio | GCST90314797 | 8.87e-03 |
| 8050 | Omega-6 fatty acid levels | GCST90502100 | 8.86e-03 |
| 8051 | Linoleic acid to total fatty acids percentage | GCST90502337 | 8.85e-03 |
| 8052 | Phospholipids to Total Lipids in Very Large HDL percentage | GCST90500474 | 8.84e-03 |
| 8053 | CSNK2A1 levels | GCST90468889 | 8.81e-03 |
| 8054 | Hair colour (natural, before greying): Red (UKB data field 1747_2) | GCST90041837 | 8.81e-03 |
| 8055 | ERBB4/UMOD ratio | GCST90314692 | 8.81e-03 |
| 8056 | PVALB levels | GCST90470393 | 8.80e-03 |
| 8057 | BACH1 levels | GCST90468415 | 8.79e-03 |
| 8058 | BLMH levels | GCST90468447 | 8.79e-03 |
| 8059 | HLA-DMA levels | GCST90241448 | 8.78e-03 |
| 8060 | Panic attacks | Mental distress | UKBB00000634 | 8.76e-03 |
| 8061 | Diacylglycerol_36:2_[M+H-H2O]1+ levels | GCST90060191 | 8.74e-03 |
| 8062 | HPCAL1/MPIG6B ratio | GCST90315073 | 8.73e-03 |
| 8063 | Hearing difficulty and hearing difficulty with background noise | GCST90245776 | 8.72e-03 |
| 8064 | Gestational thrombocytopenia | GCST90302234 | 8.69e-03 |
| 8065 | FOXO1/MAP4K5 ratio | GCST90314872 | 8.66e-03 |
| 8066 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T474 | ECGU000474 | 8.66e-03 |
| 8067 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502593 | 8.65e-03 |
| 8068 | Insulin pump user (PheCode 250.3) | GCST90475680 | 8.65e-03 |
| 8069 | Neutrophil count | GCST90018748 | 8.64e-03 |
| 8070 | DTI autoptx L3 ilf l tract | GCST90385207 | 8.63e-03 |
| 8071 | Operative procedures - Unspecified diagnostic endoscopic examination of colon | Summary Operations | UKBB00000591 | 8.59e-03 |
| 8072 | Tiglylcarnitine (C5:1-DC) levels | GCST90199800 | 8.55e-03 |
| 8073 | Left bundle branch block (PheCode 426.32) | GCST90475958 | 8.54e-03 |
| 8074 | NPDC1/PTGDS ratio | GCST90315549 | 8.54e-03 |
| 8075 | CD93/CLEC14A ratio | GCST90313921 | 8.53e-03 |
| 8076 | 1-stearoyl-2-docosahexaenoyl-gpc (18:0/22:6) levels | GCST90200046 | 8.53e-03 |
| 8077 | Alkenylphosphatidylcholine (P-36:3) levels | GCST90024954 | 8.52e-03 |
| 8078 | Docosahexaenoic acid to total fatty acids percentage | GCST90502280 | 8.50e-03 |
| 8079 | LEG1 levels | GCST90469753 | 8.49e-03 |
| 8080 | Bread type - Wholemeal or wholegrain | Diet | UKBB00000107 | 8.47e-03 |
| 8081 | IDO1 levels | GCST90469506 | 8.47e-03 |
| 8082 | Glucose levels | GCST90018735 | 8.46e-03 |
| 8083 | GALNT2 levels | GCST90469296 | 8.45e-03 |
| 8084 | Common executive function | GCST90503115 | 8.45e-03 |
| 8085 | Vegetables liking | GCST90094862 | 8.45e-03 |
| 8086 | Deep venous thrombosis | GCST90468122 | 8.44e-03 |
| 8087 | red blood cell count (RBC, maximum, inv-norm transformed) | GCST90476345 | 8.42e-03 |
| 8088 | MGAT2 levels | GCST90089560 | 8.41e-03 |
| 8089 | Asthma | GCST90086047 | 8.41e-03 |
| 8090 | BACH1/NFATC1 ratio | GCST90313444 | 8.40e-03 |
| 8091 | CRELD2/NUCB2 ratio | GCST90314256 | 8.38e-03 |
| 8092 | AXL/IL18BP ratio | GCST90313420 | 8.38e-03 |
| 8093 | ADGRG1 levels | GCST90468240 | 8.38e-03 |
| 8094 | Plasma X-24544 levels in chronic kidney disease | GCST90266757 | 8.36e-03 |
| 8095 | Degree of unsaturation | GCST90502224 | 8.36e-03 |
| 8096 | CD302/IL12A_IL12B ratio | GCST90313806 | 8.35e-03 |
| 8097 | Dimethylglycine levels | GCST90200424 | 8.34e-03 |
| 8098 | SCLY/SORD ratio | GCST90315816 | 8.33e-03 |
| 8099 | CASP3/SERPINB9 ratio | GCST90313642 | 8.33e-03 |
| 8100 | Dried fruit liking | GCST90094756 | 8.32e-03 |
| 8101 | DVT of lower extremities | FING00000482 | 8.31e-03 |
| 8102 | Takes medication for enlarged prostate (Benign prostatic hyperplasia)? | GCST90475262 | 8.30e-03 |
| 8103 | CDKN1A/PLA2G4A ratio | GCST90313974 | 8.27e-03 |
| 8104 | CCL13 levels | GCST90468565 | 8.27e-03 |
| 8105 | Principal component-derived dietary pattern 4 | GCST90133009 | 8.26e-03 |
| 8106 | EFNA1 levels | GCST90469080 | 8.24e-03 |
| 8107 | Triacylglycerol_56:5_[M+NH4]1+ levels | GCST90060554 | 8.24e-03 |
| 8108 | ARHGAP25 levels | GCST90242651 | 8.21e-03 |
| 8109 | IDP SWI T2star left pallidum | GCST90003869 | 8.20e-03 |
| 8110 | Type 2 diabetes | GCST010118 | 8.19e-03 |
| 8111 | DTI TBSS L2 Superior fronto-occipital fasciculus R | GCST90384518 | 8.18e-03 |
| 8112 | IGSF3 levels | GCST90469539 | 8.18e-03 |
| 8113 | Edema (PheCode 782.3) | GCST90476272 | 8.18e-03 |
| 8114 | LGALS3 levels | GCST90469761 | 8.17e-03 |
| 8115 | IDP dMRI TBSS L1 Superior longitudinal fasciculus R | GCST90004115 | 8.15e-03 |
| 8116 | Cholesterol in Medium LDL | GCST90498707 | 8.13e-03 |
| 8117 | ALB levels | GCST90092807 | 8.13e-03 |
| 8118 | PADI2 levels | GCST90470142 | 8.13e-03 |
| 8119 | CTBS levels | GCST90468900 | 8.12e-03 |
| 8120 | Gallbladder polyp | GCST90018626 | 8.11e-03 |
| 8121 | Dronedarone medication | FING00000474 | 8.10e-03 |
| 8122 | Hair colour (natural, before greying): Dark brown (UKB data field 1747_4) | GCST90041839 | 8.09e-03 |
| 8123 | DTI TBSS L3 Sagittal stratum R | GCST90384554 | 8.09e-03 |
| 8124 | Hair colour (natural, before greying): Light brown (UKB data field 1747_3) | GCST90041838 | 8.08e-03 |
| 8125 | Valine levels | GCST90092995 | 8.07e-03 |
| 8126 | HippSubfield rh volume CA3-body | GCST90002702 | 8.06e-03 |
| 8127 | T1 FreeSurfer pial rh lateraloccipital area | GCST90385832 | 8.06e-03 |
| 8128 | CHI3L1 levels | GCST90468743 | 8.06e-03 |
| 8129 | CDH17 levels | GCST90468669 | 8.05e-03 |
| 8130 | MZB1 levels | GCST90469987 | 8.05e-03 |
| 8131 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475448 | 8.03e-03 |
| 8132 | APOB/APOA1 ratio | GCST90092810 | 8.03e-03 |
| 8133 | Concentration of chylomicrons and extremely large VLDL particles | GCST90501010 | 8.03e-03 |
| 8134 | Fluid intelligence score decline (difference score) | GCST90565862 | 8.02e-03 |
| 8135 | Phosphatidylcholine-O_44:5_[M+OAc]1-/Phosphatidylcholine-P_44:4_[M+OAc]1- levels | GCST90060557 | 8.02e-03 |
| 8136 | Frequency of stair climbing in last 4 weeks | Physical activity | UKBB00000266 | 8.02e-03 |
| 8137 | Bone marrow fat fraction of lumbar vertebra 1 | GCST90652386 | 8.01e-03 |
| 8138 | CSPG4 levels | GCST90468890 | 8.01e-03 |
| 8139 | Cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23580) | GCST90269677 | 7.99e-03 |
| 8140 | Glutamine levels | GCST90497285 | 7.99e-03 |
| 8141 | CD83/TNFRSF4 ratio | GCST90313907 | 7.99e-03 |
| 8142 | SRC/TBL1X ratio | GCST90315884 | 7.96e-03 |
| 8143 | Type 2 diabetes | GCST90468151 | 7.95e-03 |
| 8144 | Restless leg syndrome | FING00001255 | 7.92e-03 |
| 8145 | T1 FreeSurfer DK rh lateraloccipital volume | GCST90385767 | 7.91e-03 |
| 8146 | DCTN1/SCAMP3 ratio | GCST90314433 | 7.89e-03 |
| 8147 | IZUMO4 levels | GCST90423792 | 7.87e-03 |
| 8148 | RTN4R levels | GCST90470508 | 7.86e-03 |
| 8149 | CNST levels | GCST90468801 | 7.84e-03 |
| 8150 | CD74/TNFRSF21 ratio | GCST90313897 | 7.79e-03 |
| 8151 | ENO2/SCRN1 ratio | GCST90314668 | 7.79e-03 |
| 8152 | CD84/SORT1 ratio | GCST90313918 | 7.78e-03 |
| 8153 | Total lipids in large HDL | GCST90497815 | 7.76e-03 |
| 8154 | Worrier / anxious feelings | Mental health | UKBB00000921 | 7.75e-03 |
| 8155 | Biological Mother: Cancer, Skin | GCST90475487 | 7.73e-03 |
| 8156 | Age at first sexual intercourse | GCST90000046 | 7.72e-03 |
| 8157 | Isoleucine levels | GCST90092843 | 7.72e-03 |
| 8158 | Ulcerative enterocolitis | FING00001391 | 7.71e-03 |
| 8159 | Lipoma of skin and subcutaneous tissue (PheCode 214.1) | GCST90475619 | 7.69e-03 |
| 8160 | EGFLAM levels | GCST90421651 | 7.67e-03 |
| 8161 | Prescriptions - orlistat | lipase inhibitor,obesity | UKBB00000695 | 7.67e-03 |
| 8162 | Prescriptions - lipase inhibitor|obesity | UKBB00000688 | 7.67e-03 |
| 8163 | Free cholesterol in LDL (UKB data field 23421) | GCST90269518 | 7.66e-03 |
| 8164 | Cholesteryl Esters in HDL | GCST90497368 | 7.65e-03 |
| 8165 | Unspecified acute lower respiratory infection | FING00001398 | 7.64e-03 |
| 8166 | Total lipids in very large VLDL | GCST90500607 | 7.63e-03 |
| 8167 | F-vegetarian liking (derived food-liking factor) | GCST90094863 | 7.58e-03 |
| 8168 | rfMRI amplitudes (ICA100 node 15) | GCST90004603 | 7.55e-03 |
| 8169 | Alanine transaminase (ALT, mean, inv-norm transformed) | GCST90475112 | 7.54e-03 |
| 8170 | Phospholipids in very large VLDL | GCST90500644 | 7.50e-03 |
| 8171 | Phosphatidylinositol-O_36:0_[M-H]1- levels | GCST90060480 | 7.48e-03 |
| 8172 | ANXA3/HCLS1 ratio | GCST90313282 | 7.48e-03 |
| 8173 | FUT8/VEGFC ratio | GCST90314896 | 7.46e-03 |
| 8174 | MMP12 levels | GCST90469916 | 7.45e-03 |
| 8175 | BTN2A1/SPINT2 ratio | GCST90313550 | 7.43e-03 |
| 8176 | Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditions | UKBB00000513 | 7.43e-03 |
| 8177 | F-low caloric food liking (derived food-liking factor) | GCST90094795 | 7.43e-03 |
| 8178 | SUGT1 levels | GCST90470780 | 7.43e-03 |
| 8179 | Cholesteryl esters to total lipids in very large HDL percentage (UKB data field 23631) | GCST90269728 | 7.42e-03 |
| 8180 | Androsterone sulfate levels | GCST90200674 | 7.40e-03 |
| 8181 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T467 | ECGA000467 | 7.38e-03 |
| 8182 | Drinks usually with meals in current drinkers (yes vs no) (UKB data field 1618) | GCST90132926 | 7.38e-03 |
| 8183 | Omega-3 fatty acids to total fatty acids percentage | GCST90502462 | 7.35e-03 |
| 8184 | Deviated nasal septum | FING00000409 | 7.35e-03 |
| 8185 | RNASE6 levels | GCST90470479 | 7.33e-03 |
| 8186 | Gamma glutamyltransferase levels (UKB data field 30730) | GCST90468070 | 7.31e-03 |
| 8187 | CSNK2A1 or CSNK2B levels | GCST90088963 | 7.30e-03 |
| 8188 | HDL cholesterol levels | GCST90497352 | 7.29e-03 |
| 8189 | Phospholipids in IDL (UKB data field 23525) | GCST90269622 | 7.27e-03 |
| 8190 | GZMH/KLRD1 ratio | GCST90315016 | 7.26e-03 |
| 8191 | DAG1/PLA2G4A ratio | GCST90314380 | 7.22e-03 |
| 8192 | ARSA/GUSB ratio | GCST90313355 | 7.20e-03 |
| 8193 | PDCD6IP levels | GCST90618969 | 7.20e-03 |
| 8194 | CD69/SNAP23 ratio | GCST90313886 | 7.20e-03 |
| 8195 | Cholesterol in chylomicrons and extremely large VLDL (UKB data field 23484) | GCST90269581 | 7.19e-03 |
| 8196 | ITGB1/ITGB2 ratio | GCST90315225 | 7.19e-03 |
| 8197 | Alanine levels | GCST90497085 | 7.18e-03 |
| 8198 | ACE2/GGT1 ratio | GCST90313153 | 7.18e-03 |
| 8199 | Cholesterol to Total Lipids in Very Small VLDL percentage | GCST90500731 | 7.18e-03 |
| 8200 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T484 | ECGA000484 | 7.15e-03 |
| 8201 | Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093043 | 7.15e-03 |
| 8202 | Total Alkenylphosphatidylcholine levels | GCST90025835 | 7.15e-03 |
| 8203 | Concentration of IDL particles (UKB data field 23523) | GCST90269620 | 7.14e-03 |
| 8204 | Eicosenoylcarnitine (C20:1) levels | GCST90200148 | 7.13e-03 |
| 8205 | CFB levels | GCST90468723 | 7.11e-03 |
| 8206 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502592 | 7.09e-03 |
| 8207 | MAP2K1 levels | GCST90469851 | 7.09e-03 |
| 8208 | 1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (p-16:0/18:2) levels | GCST90200075 | 7.09e-03 |
| 8209 | ELOA/MAD1L1 ratio | GCST90314640 | 7.08e-03 |
| 8210 | X-14626 levels | GCST90243861 | 7.08e-03 |
| 8211 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502166 | 7.06e-03 |
| 8212 | Secondary hypothyroidism (PheCode 244.1) | GCST90475649 | 7.06e-03 |
| 8213 | LAMP3/PRSS8 ratio | GCST90315275 | 7.04e-03 |
| 8214 | DKK1 levels | GCST90468997 | 7.03e-03 |
| 8215 | CD74/NPDC1 ratio | GCST90313895 | 7.03e-03 |
| 8216 | CD164/LGMN ratio | GCST90313741 | 7.03e-03 |
| 8217 | PIK3IP1/TNFRSF1A ratio | GCST90315653 | 7.02e-03 |
| 8218 | Left-hemisphere salience/ventral attention network to pallidum white-matter structural connectivity | GCST90302722 | 7.02e-03 |
| 8219 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T481 | ECGU000481 | 7.02e-03 |
| 8220 | Fasting glucose | GCST90278628 | 7.01e-03 |
| 8221 | SEMA3F levels | GCST90470570 | 7.01e-03 |
| 8222 | 1-(1-enyl-stearoyl)-GPE (p-18:0) levels | GCST90199910 | 7.01e-03 |
| 8223 | Thyrotoxicosis with toxic multinodular goitre | FING00001362 | 7.01e-03 |
| 8224 | PPP1R2/TMSB10 ratio | GCST90315721 | 7.01e-03 |
| 8225 | CEACAM1/GGT1 ratio | GCST90314000 | 7.00e-03 |
| 8226 | Operation code - appendicectomy | Operations | UKBB00000549 | 6.99e-03 |
| 8227 | BCR/NFATC1 ratio | GCST90313496 | 6.98e-03 |
| 8228 | Cholesterol to Total Lipids in Medium HDL percentage | GCST90498516 | 6.98e-03 |
| 8229 | Seen a psychiatrist for nerves, anxiety, tension or depression | Mental health | UKBB00000764 | 6.97e-03 |
| 8230 | HSD17B14 levels | GCST90469483 | 6.96e-03 |
| 8231 | RNF41 levels | GCST90470485 | 6.95e-03 |
| 8232 | T1 FreeSurfer a2009s rh S temporal sup volume | GCST90385110 | 6.95e-03 |
| 8233 | Concentration of VLDL particles | GCST90500250 | 6.95e-03 |
| 8234 | ARHGEF5 levels | GCST90468360 | 6.94e-03 |
| 8235 | Sleep apnea | GCST90475824 | 6.94e-03 |
| 8236 | CKAP4/LAMP3 ratio | GCST90314073 | 6.92e-03 |
| 8237 | RAB10 levels | GCST90470403 | 6.92e-03 |
| 8238 | IDI2 levels | GCST90469505 | 6.92e-03 |
| 8239 | TNFRSF4/TNFRSF8 ratio | GCST90315938 | 6.91e-03 |
| 8240 | Allergic conjunctivitis | FING00000067 | 6.87e-03 |
| 8241 | CD300C/NBL1 ratio | GCST90313792 | 6.86e-03 |
| 8242 | RGS10 levels | GCST90470465 | 6.83e-03 |
| 8243 | Hair colour (natural, before greying): Blonde (UKB data field 1747_1) | GCST90041836 | 6.83e-03 |
| 8244 | PAEP/RSPO1 ratio | GCST90315593 | 6.82e-03 |
| 8245 | TNFSF12/TNFSF13 ratio | GCST90315941 | 6.81e-03 |
| 8246 | Educational attainment (confirmatory factor analysis Factor 10) | GCST90309344 | 6.80e-03 |
| 8247 | HippSubfield rh volume GC-ML-DG-head | GCST90002701 | 6.78e-03 |
| 8248 | LYPD8 levels | GCST90469829 | 6.77e-03 |
| 8249 | EGF levels | GCST90469086 | 6.76e-03 |
| 8250 | Mean corpuscular hemoglobin concentration | GCST90018745 | 6.75e-03 |
| 8251 | Feeling hurt | GCST006951 | 6.73e-03 |
| 8252 | DTI autoptx L2 ifo r tract | GCST90385179 | 6.73e-03 |
| 8253 | CEP20 levels | GCST90468712 | 6.71e-03 |
| 8254 | CD99/PIK3IP1 ratio | GCST90313929 | 6.71e-03 |
| 8255 | Regional enteritis (PheCode 555.1) | GCST90476066 | 6.71e-03 |
| 8256 | Phosphatidylcholine_36:5_[M+H]1+/Phosphatidylethanolamine_39:5_[M+H]1+/Phosphatidate_41:6_[M+NH4]1+ levels | GCST90060345 | 6.71e-03 |
| 8257 | Sensorineural hearing loss | FING00001291 | 6.70e-03 |
| 8258 | NECTIN4 levels | GCST90470021 | 6.69e-03 |
| 8259 | T1 FreeSurfer DK rh fusiform volume | GCST90385763 | 6.69e-03 |
| 8260 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T230 | ECGU000230 | 6.67e-03 |
| 8261 | Concentration of LDL particles (UKB data field 23429) | GCST90269526 | 6.67e-03 |
| 8262 | FCRL5/ICAM3 ratio | GCST90314802 | 6.67e-03 |
| 8263 | PCDH17/TEK ratio | GCST90315606 | 6.66e-03 |
| 8264 | PAMR1/RARRES2 ratio | GCST90315595 | 6.65e-03 |
| 8265 | Cholesteryl Esters to Total Lipids in Very Large VLDL percentage | GCST90500569 | 6.64e-03 |
| 8266 | BMP7 levels | GCST90088157 | 6.64e-03 |
| 8267 | Blood glucose levels | GCST90025986 | 6.64e-03 |
| 8268 | FTCD levels | GCST90469274 | 6.63e-03 |
| 8269 | 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) levels | GCST90200070 | 6.63e-03 |
| 8270 | IL16/NADK ratio | GCST90315152 | 6.63e-03 |
| 8271 | MITD1/WWP2 ratio | GCST90315458 | 6.61e-03 |
| 8272 | Coriander liking | GCST90094744 | 6.61e-03 |
| 8273 | Red blood cell (erythrocyte) count | Blood count | UKBB00000747 | 6.61e-03 |
| 8274 | Urine glycocholenate sulfate* levels in chronic kidney disease | GCST90265292 | 6.61e-03 |
| 8275 | Memory loss or impairment | GCST90475544 | 6.60e-03 |
| 8276 | T1 FIRST volume BrStem | GCST90383989 | 6.58e-03 |
| 8277 | FCRL5 levels | GCST90469208 | 6.57e-03 |
| 8278 | Polyneuropathy in diabetes (PheCode 250.6) | GCST90475686 | 6.56e-03 |
| 8279 | F-deep fried food liking (derived food-liking factor) | GCST90094753 | 6.56e-03 |
| 8280 | RRM2B levels | GCST90470500 | 6.55e-03 |
| 8281 | APP/EGF ratio | GCST90313322 | 6.54e-03 |
| 8282 | Hyperlipidemia | GCST90090994 | 6.52e-03 |
| 8283 | INHBC levels | GCST90469615 | 6.51e-03 |
| 8284 | Granulocyte percentage of myeloid white cells | GCST004608 | 6.51e-03 |
| 8285 | Cholesterol in IDL | GCST90497495 | 6.50e-03 |
| 8286 | Noninfectious gastroenteritis | digestive | UKBB00000526 | 6.49e-03 |
| 8287 | Hemoglobin A1c levels | GCST90018738 | 6.47e-03 |
| 8288 | Left-hemisphere dorsal attention network to right-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302697 | 6.47e-03 |
| 8289 | Glucose levels (UKB data field 23470) | GCST90269567 | 6.46e-03 |
| 8290 | EVI5 levels | GCST90469158 | 6.46e-03 |
| 8291 | PDGFA/SERPINE1 ratio | GCST90315618 | 6.45e-03 |
| 8292 | Other arthritis (FG) | FING00000964 | 6.45e-03 |
| 8293 | X-21364 levels | GCST90200566 | 6.44e-03 |
| 8294 | IL12A or IL12B levels | GCST90469548 | 6.44e-03 |
| 8295 | FIS1/HSPA1A ratio | GCST90314825 | 6.43e-03 |
| 8296 | ABHD14B/CRADD ratio | GCST90313141 | 6.43e-03 |
| 8297 | ICAM5 levels | GCST90241541 | 6.41e-03 |
| 8298 | Cholecystitis | FING00000274 | 6.41e-03 |
| 8299 | Concentration of large HDL particles | GCST90497828 | 6.40e-03 |
| 8300 | Leisure/social activities - None of the above | Social support | UKBB00000399 | 6.38e-03 |
| 8301 | QSOX1 levels | GCST90470402 | 6.37e-03 |
| 8302 | Free cholesterol in very large VLDL | GCST90500581 | 6.37e-03 |
| 8303 | N-acetylphenylalanine levels in chronic kidney disease | GCST90257537 | 6.35e-03 |
| 8304 | DTI TBSS L2 Retrolenticular part of internal capsule R | GCST90384496 | 6.33e-03 |
| 8305 | DLG4 levels | GCST90469001 | 6.33e-03 |
| 8306 | DMP1 levels | GCST90469007 | 6.33e-03 |
| 8307 | GFER/VASH1 ratio | GCST90314922 | 6.32e-03 |
| 8308 | Total cholesterol levels in HDL | GCST90132681 | 6.31e-03 |
| 8309 | Asthma-related acute respiratory infections | FING00000117 | 6.31e-03 |
| 8310 | CASP8/DDX58 ratio | GCST90313651 | 6.30e-03 |
| 8311 | HSPB6/SNCG ratio | GCST90315090 | 6.30e-03 |
| 8312 | HAVCR2 levels | GCST90421515 | 6.29e-03 |
| 8313 | ICA1/YTHDF3 ratio | GCST90315113 | 6.29e-03 |
| 8314 | ADGRE2/B4GALT1 ratio | GCST90313174 | 6.28e-03 |
| 8315 | CPB1/REG1A ratio | GCST90314212 | 6.27e-03 |
| 8316 | SNX9 levels | GCST90470703 | 6.27e-03 |
| 8317 | Doctor diagnosed hayfever or allergic rhinitis | Medical information | UKBB00000192 | 6.27e-03 |
| 8318 | CA1/HMBS ratio | GCST90313573 | 6.26e-03 |
| 8319 | ELOA/POLR2F ratio | GCST90314643 | 6.26e-03 |
| 8320 | LGALS1/LGALS8 ratio | GCST90315314 | 6.25e-03 |
| 8321 | PVR levels | GCST90470394 | 6.24e-03 |
| 8322 | GRAP2/PPP1R2 ratio | GCST90314985 | 6.23e-03 |
| 8323 | VNN1 levels | GCST90471043 | 6.22e-03 |
| 8324 | Mean bone marrow fat fraction of thoracic vertebrae 8-12 | GCST90652385 | 6.21e-03 |
| 8325 | AIFM1/SIRT2 ratio | GCST90313221 | 6.20e-03 |
| 8326 | RSPO3 levels | GCST90470504 | 6.19e-03 |
| 8327 | CANT1/GSTA1 ratio | GCST90313616 | 6.18e-03 |
| 8328 | AGRP/CCN1 ratio | GCST90313202 | 6.18e-03 |
| 8329 | Bread type: Wholemeal/wholegrain vs white and brown (UKB data field 1448) | GCST90132968 | 6.18e-03 |
| 8330 | F2R levels | GCST90469168 | 6.17e-03 |
| 8331 | CTSF/SMPDL3A ratio | GCST90314316 | 6.17e-03 |
| 8332 | LATS1 levels | GCST90469740 | 6.12e-03 |
| 8333 | Nervonoylcarnitine (C24:1) levels | GCST90200143 | 6.11e-03 |
| 8334 | Percentage of M9 (GP18) | GCST90668696 | 6.11e-03 |
| 8335 | Alanine aminotransferase levels | GCST90278617 | 6.10e-03 |
| 8336 | Cholesterol to Total Lipids in Medium VLDL percentage | GCST90498926 | 6.10e-03 |
| 8337 | Other acute lower respiratory infections | FING00000921 | 6.09e-03 |
| 8338 | PDGFB levels | GCST90470189 | 6.08e-03 |
| 8339 | Calculus of kidney and ureter | Urolithiasis | UKBB00000116 | 6.08e-03 |
| 8340 | Type 2 diabetes with neurological manifestations (PheCode 250.24) | GCST90475676 | 6.08e-03 |
| 8341 | aparc-a2009s rh area G-precuneus | GCST90003400 | 6.08e-03 |
| 8342 | CD58/TYRO3 ratio | GCST90313856 | 6.07e-03 |
| 8343 | FADD/NCK2 ratio | GCST90314770 | 6.07e-03 |
| 8344 | GRPEL1 levels | GCST90469405 | 6.04e-03 |
| 8345 | Nasal polyps | GCST90468143 | 6.04e-03 |
| 8346 | Omega-3 fatty acid levels | GCST90502062 | 6.03e-03 |
| 8347 | Hyperglyceridemia (PheCode 272.12) | GCST90475724 | 6.02e-03 |
| 8348 | CRADD/DARS1 ratio | GCST90314234 | 6.01e-03 |
| 8349 | Polyunsaturated fatty acid levels | GCST90499271 | 6.00e-03 |
| 8350 | DNA methylation PhenoAge acceleration | GCST90014292 | 6.00e-03 |
| 8351 | Other specified diseases of sebaceous glands (PheCode 706.8) | GCST90476215 | 5.99e-03 |
| 8352 | Interpolated Age of participant when operation took place | Operations | UKBB00000370 | 5.98e-03 |
| 8353 | SGSH levels | GCST90470615 | 5.97e-03 |
| 8354 | PDGFB/USP8 ratio | GCST90315633 | 5.97e-03 |
| 8355 | Medication for pain relief, constipation, heartburn - Omeprazole (e.g. Zanprol) | Medication | UKBB00000458 | 5.96e-03 |
| 8356 | Cholesteryl Esters in Small HDL | GCST90499382 | 5.96e-03 |
| 8357 | Bone marrow fat fraction of thoracic vertebra 12 | GCST90652384 | 5.95e-03 |
| 8358 | DSG2 levels | GCST90469042 | 5.93e-03 |
| 8359 | BANK1/FOXO1 ratio | GCST90313456 | 5.93e-03 |
| 8360 | Total lipid levels in chylomicrons and extremely large VLDL | GCST90501002 | 5.92e-03 |
| 8361 | Ascites (non malignant) (PheCode 572) | GCST90476090 | 5.92e-03 |
| 8362 | CALCB levels | GCST90468529 | 5.91e-03 |
| 8363 | CPA4 levels | GCST90468838 | 5.90e-03 |
| 8364 | CXCL11 levels | GCST90468924 | 5.90e-03 |
| 8365 | FBP1 levels | GCST90469195 | 5.90e-03 |
| 8366 | DSG3/FABP9 ratio | GCST90314559 | 5.90e-03 |
| 8367 | Cholesteryl esters in medium VLDL (UKB data field 23506) | GCST90269603 | 5.90e-03 |
| 8368 | NECTIN2 levels | GCST90470020 | 5.89e-03 |
| 8369 | ICAM4 levels | GCST90469501 | 5.88e-03 |
| 8370 | Hearing difficulty | GCST90245774 | 5.88e-03 |
| 8371 | Conditional arithmetic | Fluid intelligence / reasoning | UKBB00000145 | 5.86e-03 |
| 8372 | Phenylalanine levels | GCST90499228 | 5.86e-03 |
| 8373 | DTI autoptx MD ptr l tract | GCST90385239 | 5.86e-03 |
| 8374 | FURIN/INHBC ratio | GCST90314886 | 5.85e-03 |
| 8375 | FOXO1/SNAP23 ratio | GCST90314875 | 5.84e-03 |
| 8376 | Free cholesterol in medium LDL (UKB data field 23542) | GCST90269639 | 5.83e-03 |
| 8377 | Principal component-derived dietary pattern 39 | GCST90133044 | 5.83e-03 |
| 8378 | Multi-site chronic pain | Other trait | UKBB00000490 | 5.83e-03 |
| 8379 | Illnesses of siblings - Diabetes | Family history | UKBB00000350 | 5.83e-03 |
| 8380 | GPKOW/PXN ratio | GCST90314978 | 5.82e-03 |
| 8381 | Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500324 | 5.81e-03 |
| 8382 | Cholesteryl esters in chylomicrons and extremely large VLDL (UKB data field 23485) | GCST90269582 | 5.80e-03 |
| 8383 | CAPG levels | GCST90468537 | 5.78e-03 |
| 8384 | Omega-6 fatty acids to omega-3 fatty acids ratio | GCST90499194 | 5.78e-03 |
| 8385 | NT5C levels | GCST90470092 | 5.77e-03 |
| 8386 | CEACAM20 levels | GCST90468693 | 5.75e-03 |
| 8387 | Type 2 diabetes | GCST005413 | 5.74e-03 |
| 8388 | Phospholipids to Total Lipids in Small HDL percentage | GCST90499505 | 5.74e-03 |
| 8389 | CD4 levels | GCST90468636 | 5.73e-03 |
| 8390 | Degree of unsaturation | GCST90500175 | 5.72e-03 |
| 8391 | HPCAL1/PMVK ratio | GCST90315076 | 5.72e-03 |
| 8392 | GAS6 levels | GCST90469305 | 5.72e-03 |
| 8393 | Able to confide | Social support | UKBB00000004 | 5.71e-03 |
| 8394 | DTI autoptx L2 slf l tract | GCST90385187 | 5.70e-03 |
| 8395 | Type 2 diabetes | GCST90018706 | 5.70e-03 |
| 8396 | Recent trouble relaxing | Anxiety | UKBB00000745 | 5.68e-03 |
| 8397 | Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels | GCST90200103 | 5.67e-03 |
| 8398 | FABP1/RBP2 ratio | GCST90314753 | 5.63e-03 |
| 8399 | 3-Hydroxybutyrate levels | GCST90092811 | 5.63e-03 |
| 8400 | EPHB6/LAYN ratio | GCST90314681 | 5.62e-03 |
| 8401 | Cholesteryl Esters to Total Lipids in Very Large HDL percentage | GCST90500359 | 5.62e-03 |
| 8402 | DTI TBSS L1 Genu of corpus callosum | GCST90384430 | 5.61e-03 |
| 8403 | COMP/TGFBI ratio | GCST90314192 | 5.56e-03 |
| 8404 | REST UKBBICA NODEamps25 0005 | GCST90385488 | 5.55e-03 |
| 8405 | FABP4/FGF21 ratio | GCST90314758 | 5.54e-03 |
| 8406 | Autorefraction - 3mm asymmetry angle (left) | Eyesight | UKBB00000060 | 5.53e-03 |
| 8407 | S100A4 levels | GCST90470518 | 5.52e-03 |
| 8408 | Triglyceride to phosphoglyceride ratio | GCST90499996 | 5.51e-03 |
| 8409 | AmygNuclei lh volume Whole-amygdala | GCST90002657 | 5.51e-03 |
| 8410 | ENO2/ITGB1BP2 ratio | GCST90314661 | 5.50e-03 |
| 8411 | CD209/CLEC4G ratio | GCST90313750 | 5.50e-03 |
| 8412 | Pregnenetriol sulfate levels | GCST90200241 | 5.50e-03 |
| 8413 | CANT1/NUDT5 ratio | GCST90313619 | 5.49e-03 |
| 8414 | Body mass index (BMI, minimum, inv-normal transformed) | GCST90475159 | 5.49e-03 |
| 8415 | CDHR2/SSC4D ratio | GCST90313965 | 5.48e-03 |
| 8416 | Volume of right medial nucleus | GCST90475042 | 5.47e-03 |
| 8417 | Phospholipids in medium HDL (UKB data field 23567) | GCST90269664 | 5.47e-03 |
| 8418 | ANGPT1/DKK1 ratio | GCST90313263 | 5.46e-03 |
| 8419 | Cough (PheCode 512.8) | GCST90476041 | 5.45e-03 |
| 8420 | MNX1 levels | GCST90090758 | 5.44e-03 |
| 8421 | T1 FreeSurfer BA rh V2 exvivo area | GCST90385557 | 5.44e-03 |
| 8422 | SCG2 levels | GCST90470538 | 5.43e-03 |
| 8423 | Free cholesterol levels in IDL | GCST90092835 | 5.42e-03 |
| 8424 | Body fat percentage | GCST90103752 | 5.42e-03 |
| 8425 | SMPD1/SMPDL3A ratio | GCST90315854 | 5.41e-03 |
| 8426 | MMP1 levels | GCST90469919 | 5.39e-03 |
| 8427 | Crisps liking | GCST90094747 | 5.38e-03 |
| 8428 | YBX1 levels | GCST90090799 | 5.38e-03 |
| 8429 | Triacylglycerol_52:1_[M+NH4]1+ levels | GCST90060515 | 5.37e-03 |
| 8430 | IPCEF1/SMAD1 ratio | GCST90315185 | 5.37e-03 |
| 8431 | Presence of other functional implants | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000709 | 5.36e-03 |
| 8432 | aparc-DKTatlas rh volume fusiform | GCST90002898 | 5.33e-03 |
| 8433 | Ingrowing nail (PheCode 703.1) | GCST90476208 | 5.33e-03 |
| 8434 | DTI TBSS L3 Anterior limb of internal capsule R | GCST90384540 | 5.32e-03 |
| 8435 | LYN levels | GCST90469826 | 5.32e-03 |
| 8436 | Right-hemisphere control network to amygdala white-matter structural connectivity | GCST90302841 | 5.32e-03 |
| 8437 | Appendectomy | FING00000104 | 5.32e-03 |
| 8438 | Carnitine levels | GCST90243481 | 5.31e-03 |
| 8439 | Concentration of medium HDL particles | GCST90092899 | 5.31e-03 |
| 8440 | Childhood body mass index | GCST90002409 | 5.29e-03 |
| 8441 | High light scatter reticulocyte percentage | Blood count | UKBB00000327 | 5.29e-03 |
| 8442 | NECTIN4/SPINK5 ratio | GCST90315534 | 5.28e-03 |
| 8443 | Reaction time | GCST003499 | 5.27e-03 |
| 8444 | DUSP29 levels | GCST90469052 | 5.27e-03 |
| 8445 | PLXNA4/SKAP2 ratio | GCST90315685 | 5.26e-03 |
| 8446 | PECAM1/SOD2 ratio | GCST90315647 | 5.25e-03 |
| 8447 | IDP T1 SIENAX white normalised volume | GCST90002432 | 5.25e-03 |
| 8448 | Low density lipoprotein cholesterol levels | GCST90002412 | 5.24e-03 |
| 8449 | 4-hydroxyglutamate levels | GCST90199890 | 5.24e-03 |
| 8450 | Principal component-derived dietary pattern 23 | GCST90133028 | 5.23e-03 |
| 8451 | Monocyte count | GCST90002393 | 5.23e-03 |
| 8452 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T95 | ECGU000095 | 5.23e-03 |
| 8453 | Types of physical activity in last 4 weeks - Heavy DIY (eg: weeding, lawn mowing, carpentry, digging) | Physical activity | UKBB00000870 | 5.20e-03 |
| 8454 | Sphingomyelin (d18:1/16:0) levels | GCST90025744 | 5.20e-03 |
| 8455 | CRKL/FIS1 ratio | GCST90314266 | 5.20e-03 |
| 8456 | Low hand grip strength (60 years and older) (FNIH) | GCST90007529 | 5.19e-03 |
| 8457 | Malignant neoplasm of skin, excluding all cancers (controls excluding all cancers) | FING00000772 | 5.19e-03 |
| 8458 | Weekly usage of mobile phone in last 3 months | Electronic device use | UKBB00000908 | 5.19e-03 |
| 8459 | Cholesterol in large LDL (UKB data field 23533) | GCST90269630 | 5.17e-03 |
| 8460 | FHIT/PMVK ratio | GCST90314822 | 5.17e-03 |
| 8461 | GSTA1/PBLD ratio | GCST90314994 | 5.17e-03 |
| 8462 | WAS levels | GCST90471071 | 5.16e-03 |
| 8463 | Fatty acid(20:3)_[M-H]1- levels | GCST90060117 | 5.16e-03 |
| 8464 | ENO2 levels | GCST90469110 | 5.16e-03 |
| 8465 | CD20 on IgD- CD24- B cell | GCST90001753 | 5.15e-03 |
| 8466 | Daytime dozing / sleeping (narcolepsy) | Sleep | UKBB00000164 | 5.13e-03 |
| 8467 | SF3B4/SIRT2 ratio | GCST90315838 | 5.11e-03 |
| 8468 | BCR/GOPC ratio | GCST90313491 | 5.11e-03 |
| 8469 | monocyte (absolute count, mean, inv-norm transformed) | GCST90475502 | 5.10e-03 |
| 8470 | PPBP levels | GCST90470289 | 5.10e-03 |
| 8471 | Cardiorespiratory fitness slope | GCST90093320 | 5.09e-03 |
| 8472 | DCTN1 levels | GCST90468958 | 5.09e-03 |
| 8473 | SERPINB13 levels | GCST90423326 | 5.09e-03 |
| 8474 | ENPP5 levels | GCST90469116 | 5.07e-03 |
| 8475 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T86 | ECGU000086 | 5.07e-03 |
| 8476 | Total lipids in very large HDL | GCST90500410 | 5.04e-03 |
| 8477 | Bone marrow fat fraction of thoracic vertebra 11 | GCST90652383 | 5.03e-03 |
| 8478 | Principal component-derived dietary pattern 45 | GCST90133050 | 5.03e-03 |
| 8479 | ABHD14B levels | GCST90468189 | 5.03e-03 |
| 8480 | SERPINE1/USP8 ratio | GCST90315835 | 5.03e-03 |
| 8481 | ARTN levels | GCST90468372 | 5.02e-03 |
| 8482 | ASGR1/GGT5 ratio | GCST90313365 | 5.01e-03 |
| 8483 | AXIN1/DOK2 ratio | GCST90313406 | 5.00e-03 |
| 8484 | Cholesteryl esters in large LDL (UKB data field 23534) | GCST90269631 | 5.00e-03 |
| 8485 | rfMRI connectivity (ICA100 edge 1090) | GCST90005943 | 5.00e-03 |
| 8486 | Cholesterol_[M+H-H2O]1+ levels | GCST90060133 | 4.99e-03 |
| 8487 | HYAL1 levels | GCST90469495 | 4.99e-03 |
| 8488 | CDH3 levels | GCST90468674 | 4.96e-03 |
| 8489 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T82 | ECGU000082 | 4.95e-03 |
| 8490 | TDGF1 levels | GCST90470824 | 4.94e-03 |
| 8491 | HGS levels | GCST90469450 | 4.94e-03 |
| 8492 | Lung cancer | GCST90018655 | 4.93e-03 |
| 8493 | Phospholipids in very large VLDL (UKB data field 23490) | GCST90269587 | 4.93e-03 |
| 8494 | Percentage of M9 (GP18) | GCST90668462 | 4.93e-03 |
| 8495 | CLEC1B/HEXIM1 ratio | GCST90314093 | 4.92e-03 |
| 8496 | Interpolated Year when operation took place | Operations | UKBB00000372 | 4.92e-03 |
| 8497 | Malignant neoplasm of breast, excluding all cancers (controls excluding all cancers) | FING00000755 | 4.92e-03 |
| 8498 | DTI autoptx L1 ptr r tract | GCST90385159 | 4.90e-03 |
| 8499 | Hypertension | GCST90086091 | 4.90e-03 |
| 8500 | Ever suffered mental distress preventing usual activities | Mental distress | UKBB00000223 | 4.90e-03 |
| 8501 | AmygNuclei rh volume Paralaminar-nucleus | GCST90002666 | 4.90e-03 |
| 8502 | TRIAP1 levels | GCST90470963 | 4.89e-03 |
| 8503 | monocyte (fraction, maximum, inv-norm transformed) | GCST90475508 | 4.88e-03 |
| 8504 | IDP dMRI ProbtrackX ICVF ml l | GCST90004392 | 4.88e-03 |
| 8505 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T493 | ECGU000493 | 4.88e-03 |
| 8506 | CNTNAP2 levels | GCST90468808 | 4.88e-03 |
| 8507 | TGFBR2/TNFRSF1A ratio | GCST90315918 | 4.88e-03 |
| 8508 | Ulcerative colitis | GCST90446795 | 4.85e-03 |
| 8509 | Type of accommodation lived in - A house or bungalow | Household | UKBB00000869 | 4.84e-03 |
| 8510 | TNFRSF13B/TNFSF13B ratio | GCST90315933 | 4.84e-03 |
| 8511 | CDH5/PEAR1 ratio | GCST90313959 | 4.84e-03 |
| 8512 | Lawsonibacter sp002161175 abundance in stool | GCST90032459 | 4.83e-03 |
| 8513 | CLEC4A levels | GCST90468771 | 4.83e-03 |
| 8514 | LECT2 levels | GCST90469751 | 4.83e-03 |
| 8515 | Cholesteryl Esters to Total Lipids in Medium HDL percentage | GCST90498556 | 4.83e-03 |
| 8516 | CD160/KLRB1 ratio | GCST90313731 | 4.82e-03 |
| 8517 | NAGPA levels | GCST90469996 | 4.81e-03 |
| 8518 | Phospholipids in small HDL | GCST90499483 | 4.81e-03 |
| 8519 | HGF/PDGFB ratio | GCST90315058 | 4.81e-03 |
| 8520 | Other disorders of ear | FING00001023 | 4.81e-03 |
| 8521 | CAPN3 levels | GCST90468538 | 4.80e-03 |
| 8522 | Pregnancy with abortive outcome | FING00001205 | 4.80e-03 |
| 8523 | IDP dMRI TBSS ISOVF Anterior corona radiata L | GCST90004500 | 4.80e-03 |
| 8524 | GOLM2/ITGA5 ratio | GCST90314951 | 4.80e-03 |
| 8525 | HBEGF/PDGFB ratio | GCST90315034 | 4.77e-03 |
| 8526 | EGFL7 levels | GCST90469083 | 4.76e-03 |
| 8527 | White blood cell count | GCST90002374 | 4.76e-03 |
| 8528 | Mean platelet volume during the postpartum period | GCST90302233 | 4.76e-03 |
| 8529 | Bipolar disorder | GCST003724 | 4.75e-03 |
| 8530 | Bundle branch block (PheCode 426.3) | GCST90475956 | 4.73e-03 |
| 8531 | Use of disulfiram, acamprosate or naltrexone | FING00001410 | 4.72e-03 |
| 8532 | DCTPP1 levels | GCST90468961 | 4.71e-03 |
| 8533 | Takes medication for prostate cancer? | GCST90475187 | 4.70e-03 |
| 8534 | BACH1/EIF4G1 ratio | GCST90313438 | 4.69e-03 |
| 8535 | Never eat eggs, dairy, wheat, sugar - Sugar or foods/drinks containing sugar | Diet | UKBB00000501 | 4.68e-03 |
| 8536 | Free cholesterol in very large VLDL (UKB data field 23493) | GCST90269590 | 4.67e-03 |
| 8537 | HVEM on Terminally Differentiated CD4+ T cell | GCST90001879 | 4.67e-03 |
| 8538 | Other non-epithelial cancer of skin (PheCode 172.2) | GCST90475580 | 4.67e-03 |
| 8539 | GDI2 levels | GCST90088004 | 4.66e-03 |
| 8540 | Monocyte count (UKB data field 30130) | GCST90468090 | 4.66e-03 |
| 8541 | Free cholesterol to total lipids in large HDL percentage (UKB data field 23637) | GCST90269734 | 4.66e-03 |
| 8542 | aparc-DKTatlas lh volume caudalanteriorcingulate | GCST90002863 | 4.66e-03 |
| 8543 | VPS53 levels | GCST90471048 | 4.64e-03 |
| 8544 | Alcohol consumption | GCST90133003 | 4.64e-03 |
| 8545 | Cholesterol to total lipids in medium HDL percentage (UKB data field 23640) | GCST90269737 | 4.63e-03 |
| 8546 | MLN levels | GCST90469913 | 4.61e-03 |
| 8547 | Phenylalanine levels | GCST90092936 | 4.61e-03 |
| 8548 | CXCL13 levels | GCST90468926 | 4.60e-03 |
| 8549 | TNFRSF17 levels | GCST90470908 | 4.59e-03 |
| 8550 | Cholesterol in Medium HDL | GCST90498495 | 4.58e-03 |
| 8551 | Linoleic acid levels | GCST90498309 | 4.58e-03 |
| 8552 | ABL1/PDLIM7 ratio | GCST90313150 | 4.57e-03 |
| 8553 | Phospholipids in LDL | GCST90498439 | 4.56e-03 |
| 8554 | ALB levels | GCST90497101 | 4.55e-03 |
| 8555 | Free Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500992 | 4.55e-03 |
| 8556 | APOA1 levels | GCST90468331 | 4.55e-03 |
| 8557 | Androstenediol (3beta,17beta) monosulfate (2) levels | GCST90199871 | 4.54e-03 |
| 8558 | Free cholesterol in large LDL (UKB data field 23535) | GCST90269632 | 4.52e-03 |
| 8559 | LCN2/PRTN3 ratio | GCST90315307 | 4.50e-03 |
| 8560 | SDHB levels | GCST90470561 | 4.50e-03 |
| 8561 | Haddock liking | GCST90094776 | 4.50e-03 |
| 8562 | MME/NT5E ratio | GCST90315460 | 4.48e-03 |
| 8563 | High light scatter reticulocyte count (UKB data field 30300) | GCST90468076 | 4.48e-03 |
| 8564 | Mean corpuscular haemoglobin concentration (UKB data field 30060) | GCST90468085 | 4.47e-03 |
| 8565 | Multiple myeloma and malignant plasma cell neoplasms (controls excluding all cancers) | FING00000843 | 4.47e-03 |
| 8566 | Triglycerides to phosphoglycerides ratio (UKB data field 23435) | GCST90269532 | 4.47e-03 |
| 8567 | Valine levels | GCST90132752 | 4.46e-03 |
| 8568 | HDL cholesterol levels | GCST90497340 | 4.46e-03 |
| 8569 | CTRB1/KIRREL2 ratio | GCST90314306 | 4.46e-03 |
| 8570 | Phospholipids to total lipids ratio in large VLDL | GCST90092877 | 4.45e-03 |
| 8571 | DTI TBSS L3 Cingulum hippocampus L | GCST90384561 | 4.45e-03 |
| 8572 | Small cell lung carcinoma | GCST004746 | 4.45e-03 |
| 8573 | Total cholesterol minus HDL-C levels (UKB data field 23401) | GCST90269498 | 4.45e-03 |
| 8574 | 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) levels | GCST90199649 | 4.44e-03 |
| 8575 | Total lipids in very large VLDL (UKB data field 23489) | GCST90269586 | 4.44e-03 |
| 8576 | Rheumatoid arthritis and other inflammatory (PheCode 714) | GCST90476228 | 4.43e-03 |
| 8577 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T492 | ECGU000492 | 4.43e-03 |
| 8578 | BSG/TNFRSF4 ratio | GCST90313536 | 4.42e-03 |
| 8579 | Intelligence | GCST004364 | 4.40e-03 |
| 8580 | SPRY2/YTHDF3 ratio | GCST90315881 | 4.40e-03 |
| 8581 | Bone marrow fat fraction of thoracic vertebra 9 | GCST90652381 | 4.39e-03 |
| 8582 | Acute appendicitis, with complications | FING00000019 | 4.38e-03 |
| 8583 | Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500929 | 4.38e-03 |
| 8584 | Educational attainment | GCST002598 | 4.37e-03 |
| 8585 | CD226 levels | GCST90468609 | 4.36e-03 |
| 8586 | Phospholipids in IDL | GCST90497628 | 4.36e-03 |
| 8587 | Migraine | FING00000818 | 4.36e-03 |
| 8588 | IDUA levels | GCST90469508 | 4.35e-03 |
| 8589 | Sphingomyelin_33:1_[M+H]1+ levels | GCST90060229 | 4.34e-03 |
| 8590 | Phospholipids in LDL (UKB data field 23413) | GCST90269510 | 4.34e-03 |
| 8591 | Degenerative skin conditions and other dermatoses (PheCode 702) | GCST90476202 | 4.34e-03 |
| 8592 | PARP1/TCL1A ratio | GCST90315602 | 4.33e-03 |
| 8593 | Lung adenocarcinoma | GCST004744 | 4.33e-03 |
| 8594 | 1-linoleoyl-GPI (18:2) levels | GCST90199821 | 4.33e-03 |
| 8595 | Cereal bar liking | GCST90094728 | 4.33e-03 |
| 8596 | Free cholesterol in IDL | GCST90497564 | 4.33e-03 |
| 8597 | APOB levels | GCST90269536 | 4.32e-03 |
| 8598 | Cholesteryl esters in very large VLDL (UKB data field 23492) | GCST90269589 | 4.32e-03 |
| 8599 | RGMB levels | GCST90242647 | 4.31e-03 |
| 8600 | Transport type for commuting to job workplace - Public transport | Employment | UKBB00000828 | 4.30e-03 |
| 8601 | EIF4G1/NFATC1 ratio | GCST90314637 | 4.30e-03 |
| 8602 | DTI autoptx L2 ifo l tract | GCST90385178 | 4.30e-03 |
| 8603 | ATP5IF1/DECR1 ratio | GCST90313382 | 4.29e-03 |
| 8604 | Total lipids in large LDL (UKB data field 23531) | GCST90269628 | 4.29e-03 |
| 8605 | Number of vehicles in household | Household | UKBB00000543 | 4.28e-03 |
| 8606 | Saturated fatty acids to total fatty acids percentage | GCST90502205 | 4.28e-03 |
| 8607 | PLIN3/TYMP ratio | GCST90315678 | 4.28e-03 |
| 8608 | Childhood asthma (age<16) (more control exclusions) | FING00000270 | 4.27e-03 |
| 8609 | Illnesses of mother - Diabetes | Family history | UKBB00000347 | 4.27e-03 |
| 8610 | KIR2DL2 levels | GCST90469684 | 4.27e-03 |
| 8611 | Seronegative rheumatoid arthritis | FING00001296 | 4.26e-03 |
| 8612 | Plays computer games | Electronic device use | UKBB00000649 | 4.25e-03 |
| 8613 | Concentration of very large VLDL particles | GCST90500628 | 4.22e-03 |
| 8614 | Hair colour (natural, before greying) - Light brown | Sun exposure | UKBB00000298 | 4.21e-03 |
| 8615 | ADIPOQ levels | GCST90468245 | 4.20e-03 |
| 8616 | IFNLR1 levels | GCST90469518 | 4.19e-03 |
| 8617 | Reticulocyte count | Blood count | UKBB00000752 | 4.17e-03 |
| 8618 | BCR/FOXO1 ratio | GCST90313490 | 4.17e-03 |
| 8619 | Free Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500593 | 4.16e-03 |
| 8620 | Paraproteinemia (PheCode 270.32) | GCST90475710 | 4.16e-03 |
| 8621 | Medical abortion | FING00000796 | 4.16e-03 |
| 8622 | Triglycerides in very large VLDL (UKB data field 23494) | GCST90269591 | 4.15e-03 |
| 8623 | COX5B/FXN ratio | GCST90314199 | 4.15e-03 |
| 8624 | Nasal polyp | FING00000858 | 4.14e-03 |
| 8625 | TOP1 levels | GCST90470933 | 4.13e-03 |
| 8626 | Diseases of oesophagus, stomach and duodenum | FING00000428 | 4.13e-03 |
| 8627 | TF levels | GCST90470841 | 4.11e-03 |
| 8628 | Phospholipids to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501045 | 4.11e-03 |
| 8629 | HLA-A levels | GCST90469457 | 4.11e-03 |
| 8630 | Phospholipids to Total Lipids in Small LDL percentage | GCST90499690 | 4.11e-03 |
| 8631 | Aspartate aminotransferase (AST, mean, inv-norm transformed) | GCST90475121 | 4.11e-03 |
| 8632 | CD300C/LRRC25 ratio | GCST90313790 | 4.10e-03 |
| 8633 | Retinal thickness (functional principal component 1) | GCST90455721 | 4.10e-03 |
| 8634 | SMPDL3A levels | GCST90470686 | 4.10e-03 |
| 8635 | Cholesterol in Small HDL | GCST90499348 | 4.10e-03 |
| 8636 | CRTAM/FCRL6 ratio | GCST90314274 | 4.09e-03 |
| 8637 | Volume of left central nucleus | GCST90474958 | 4.09e-03 |
| 8638 | CD5 levels | GCST90274773 | 4.08e-03 |
| 8639 | Hair colour (natural, before greying) - Blonde | Sun exposure | UKBB00000296 | 4.08e-03 |
| 8640 | Behaviour of cancer tumour: malignant, primary site, PHESANT recoding (UKB data field 40012_3) | GCST90043946 | 4.08e-03 |
| 8641 | Rhodanobacter abundance in stool | GCST90032536 | 4.08e-03 |
| 8642 | Exposure to tobacco smoke at home | Smoking | UKBB00000228 | 4.07e-03 |
| 8643 | High light scatter reticulocyte percentage of red cells | GCST90002386 | 4.06e-03 |
| 8644 | CLTA levels | GCST90468791 | 4.06e-03 |
| 8645 | Spread type: Butter/spreadable butter (UKB data field 1428_1) | GCST90132953 | 4.06e-03 |
| 8646 | LY96/ST6GAL1 ratio | GCST90315348 | 4.05e-03 |
| 8647 | Diacylglycerol_33:1_[M+H-H2O]1+ levels | GCST90060173 | 4.05e-03 |
| 8648 | Cholelithiasis | GCST90468118 | 4.05e-03 |
| 8649 | Treatment speciality of consultant (recoded) - Trauma & orthopaedics | Summary Administration | UKBB00000837 | 4.05e-03 |
| 8650 | Birth asphyxia | FING00000218 | 4.04e-03 |
| 8651 | SERPINA6 levels | GCST90470586 | 4.04e-03 |
| 8652 | Spermatocele | FING00001319 | 4.03e-03 |
| 8653 | Physical activity (Total log acceleration) | GCST90061408 | 4.03e-03 |
| 8654 | PRND levels | GCST90470333 | 4.02e-03 |
| 8655 | Exophthalmic conditions | FING00000526 | 4.01e-03 |
| 8656 | Staphylococcus A fleurettii abundance in stool | GCST90032564 | 4.01e-03 |
| 8657 | LMNB1 levels | GCST90469781 | 4.00e-03 |
| 8658 | CD163/MSR1 ratio | GCST90313738 | 3.99e-03 |
| 8659 | Cognitive processing accuracy | GCST90446169 | 3.99e-03 |
| 8660 | AmygNuclei lh volume Lateral-nucleus | GCST90002648 | 3.99e-03 |
| 8661 | Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80) | GCST90668758 | 3.97e-03 |
| 8662 | Sphingomyelins levels (UKB data field 23438) | GCST90269535 | 3.96e-03 |
| 8663 | Phospholipids to total lipids ratio in very large HDL | GCST90093013 | 3.95e-03 |
| 8664 | Free cholesterol in medium VLDL (UKB data field 23507) | GCST90269604 | 3.95e-03 |
| 8665 | KIT levels | GCST90469692 | 3.94e-03 |
| 8666 | BAG6/WASF1 ratio | GCST90313452 | 3.94e-03 |
| 8667 | Follicular lymphoma, hilmo (controls excluding all cancers) | FING00000548 | 3.94e-03 |
| 8668 | IL7R levels | GCST90469605 | 3.94e-03 |
| 8669 | FGF19 levels | GCST90469220 | 3.93e-03 |
| 8670 | ISLR2 levels | GCST90469629 | 3.93e-03 |
| 8671 | VEGFC levels | GCST90471036 | 3.92e-03 |
| 8672 | IDP T1 SIENAX white unnormalised volume | GCST90002433 | 3.92e-03 |
| 8673 | MSR1 levels | GCST90469950 | 3.92e-03 |
| 8674 | IDP T1 FAST ROIs R cerebellum VIIIa | GCST90002580 | 3.92e-03 |
| 8675 | CLEC14A/PTPRS ratio | GCST90314081 | 3.90e-03 |
| 8676 | CNDP1 levels | GCST90468796 | 3.90e-03 |
| 8677 | IDP dMRI TBSS OD Anterior limb of internal capsule R | GCST90004418 | 3.90e-03 |
| 8678 | TACC3/TBC1D23 ratio | GCST90315900 | 3.89e-03 |
| 8679 | FXN levels | GCST90469282 | 3.89e-03 |
| 8680 | DNMBP/WWP2 ratio | GCST90314522 | 3.88e-03 |
| 8681 | Body mass index | GCST90025994 | 3.88e-03 |
| 8682 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502385 | 3.87e-03 |
| 8683 | wg lh intensity-contrast parahippocampal | GCST90003807 | 3.87e-03 |
| 8684 | Type 2 diabetes, definitions combined | FING00001382 | 3.86e-03 |
| 8685 | PEAR1/TREML2 ratio | GCST90315645 | 3.86e-03 |
| 8686 | F-sauces liking (derived food-liking factor) | GCST90094831 | 3.85e-03 |
| 8687 | Feeling worry | GCST006950 | 3.84e-03 |
| 8688 | Cholesteryl Esters to Total Lipids in Very Small VLDL percentage | GCST90500764 | 3.82e-03 |
| 8689 | PDGFB/TNFSF13 ratio | GCST90315632 | 3.82e-03 |
| 8690 | Thyroid peroxidase antibody levels in pregnancy | GCST90435201 | 3.82e-03 |
| 8691 | IDP dMRI TBSS ICVF Posterior limb of internal capsule L | GCST90004346 | 3.81e-03 |
| 8692 | Sphingomyelin_42:2_[M+OAc]1- levels | GCST90060507 | 3.81e-03 |
| 8693 | CSF2RB levels | GCST90468883 | 3.79e-03 |
| 8694 | Hashimoto thyroiditis | GCST90018635 | 3.78e-03 |
| 8695 | CA2/NSFL1C ratio | GCST90313580 | 3.77e-03 |
| 8696 | Blood cell traits latent factor 4 (red cell) | GCST90559246 | 3.77e-03 |
| 8697 | RNASE1 levels | GCST90470476 | 3.76e-03 |
| 8698 | AGXT levels | GCST90468258 | 3.76e-03 |
| 8699 | Age at first sexual intercourse | GCST90000047 | 3.75e-03 |
| 8700 | CALCOCO1/PDLIM7 ratio | GCST90313607 | 3.75e-03 |
| 8701 | Phospholipids to total lipids ratio in very large VLDL | GCST90093025 | 3.75e-03 |
| 8702 | ATRAID levels | GCST90468399 | 3.74e-03 |
| 8703 | APEX1 levels | GCST90468329 | 3.74e-03 |
| 8704 | Modified Stumvoll Insulin Sensitivity Index | GCST90267574 | 3.71e-03 |
| 8705 | Concentration of very large VLDL particles (UKB data field 23488) | GCST90269585 | 3.71e-03 |
| 8706 | Diseases of hair and hair follicles (PheCode 704) | GCST90476209 | 3.70e-03 |
| 8707 | Familial combined hyperlipidemia defined by Mexico criteria | GCST90104007 | 3.70e-03 |
| 8708 | CD40 levels | GCST90012065 | 3.70e-03 |
| 8709 | Nonspecific chest pain (PheCode 418) | GCST90475947 | 3.69e-03 |
| 8710 | Bone marrow fat fraction of thoracic vertebra 8 | GCST90652380 | 3.69e-03 |
| 8711 | DRAXIN levels | GCST90469038 | 3.69e-03 |
| 8712 | AmygNuclei rh volume Basal-nucleus | GCST90002659 | 3.69e-03 |
| 8713 | RGS18 levels | GCST90242617 | 3.68e-03 |
| 8714 | Cheese intake | Diet | UKBB00000127 | 3.67e-03 |
| 8715 | VSTM2L levels | GCST90471057 | 3.67e-03 |
| 8716 | Phospholipids in large LDL (UKB data field 23532) | GCST90269629 | 3.67e-03 |
| 8717 | Other diseases of liver | FING00001004 | 3.67e-03 |
| 8718 | aparc-DKTatlas rh area insula | GCST90003296 | 3.65e-03 |
| 8719 | SERPINE1/SPARC ratio | GCST90315834 | 3.65e-03 |
| 8720 | Phospholipids to Total Lipids in Very Large VLDL percentage | GCST90500655 | 3.64e-03 |
| 8721 | LDL cholesterol levels (UKB data field 23405) | GCST90269502 | 3.64e-03 |
| 8722 | Triglycerides in VLDL | GCST90500295 | 3.61e-03 |
| 8723 | Comparative body size at age 10 | Early life factors | UKBB00000142 | 3.61e-03 |
| 8724 | Medication for pain relief, constipation, heartburn - Laxatives (e.g. Dulcolax, Senokot) | Medication | UKBB00000456 | 3.61e-03 |
| 8725 | FADD/NFATC1 ratio | GCST90314771 | 3.60e-03 |
| 8726 | ANXA3/SERPINB1 ratio | GCST90313289 | 3.60e-03 |
| 8727 | Body mass index | GCST90446645 | 3.60e-03 |
| 8728 | AK1/NSFL1C ratio | GCST90313224 | 3.59e-03 |
| 8729 | Cerebrospinal fluid proline levels | GCST90318251 | 3.59e-03 |
| 8730 | Citrate levels (UKB data field 23473) | GCST90269570 | 3.59e-03 |
| 8731 | CLEC1B/GP1BA ratio | GCST90314091 | 3.57e-03 |
| 8732 | Hair colour (natural, before greying) - Black | Sun exposure | UKBB00000295 | 3.56e-03 |
| 8733 | Attention deficit hyperactivity disorder (ADuLT model adjusted for sex) | GCST90275136 | 3.56e-03 |
| 8734 | CD83/TREM2 ratio | GCST90313908 | 3.55e-03 |
| 8735 | F11R levels | GCST90469164 | 3.55e-03 |
| 8736 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T55 | ECGA000055 | 3.55e-03 |
| 8737 | Creatinine levels (UKB data field 23478) | GCST90269575 | 3.54e-03 |
| 8738 | SULT2A1 levels | GCST90470782 | 3.54e-03 |
| 8739 | HAVCR2/TREM2 ratio | GCST90315031 | 3.54e-03 |
| 8740 | Total lipids in LDL (UKB data field 23425) | GCST90269522 | 3.53e-03 |
| 8741 | Ever worried more than most people would in similar situation | Anxiety | UKBB00000227 | 3.53e-03 |
| 8742 | Rheumatoid arthritis | GCST000679 | 3.51e-03 |
| 8743 | GLB1/IMPA1 ratio | GCST90314932 | 3.50e-03 |
| 8744 | SERPINB6/TXNDC5 ratio | GCST90315832 | 3.50e-03 |
| 8745 | ALCAM/SPINT1 ratio | GCST90313242 | 3.49e-03 |
| 8746 | Hypertrophic scar | FING00000642 | 3.49e-03 |
| 8747 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T80 | ECGU000080 | 3.48e-03 |
| 8748 | HSBP1 levels | GCST90469481 | 3.48e-03 |
| 8749 | CD38/IL12A_IL12B ratio | GCST90313808 | 3.48e-03 |
| 8750 | Diseases of sebaceous glands (PheCode 706) | GCST90476210 | 3.48e-03 |
| 8751 | Cholesteryl esters in small VLDL (UKB data field 23513) | GCST90269610 | 3.47e-03 |
| 8752 | CD58/ERBB3 ratio | GCST90313848 | 3.46e-03 |
| 8753 | aseg rh volume Amygdala | GCST90002642 | 3.46e-03 |
| 8754 | Smoking status (standard GWA) | GCST90267302 | 3.46e-03 |
| 8755 | Degree of unsaturation | GCST90502225 | 3.46e-03 |
| 8756 | Cholesteryl Esters to Total Lipids in Large VLDL percentage | GCST90498165 | 3.45e-03 |
| 8757 | Mouth/teeth dental problems - Dentures | Mouth | UKBB00000486 | 3.45e-03 |
| 8758 | Cerotoylcarnitine (C26) levels | GCST90200136 | 3.45e-03 |
| 8759 | ACY1 levels | GCST90468212 | 3.44e-03 |
| 8760 | TMEM25 levels | GCST90470888 | 3.43e-03 |
| 8761 | Degree of unsaturation | GCST90502753 | 3.43e-03 |
| 8762 | Lower back pain or/and sciatica | FING00000731 | 3.43e-03 |
| 8763 | FSTL3 levels | GCST90425765 | 3.42e-03 |
| 8764 | CHRDL1 levels | GCST90468750 | 3.41e-03 |
| 8765 | IDP dMRI ProbtrackX L1 cgc l | GCST90004250 | 3.41e-03 |
| 8766 | Handedness (chirality/laterality) - Left-handed | Early life factors | UKBB00000302 | 3.40e-03 |
| 8767 | KLK8/WFDC12 ratio | GCST90315259 | 3.40e-03 |
| 8768 | Haematocrit percentage (UKB data field 30030) | GCST90468073 | 3.39e-03 |
| 8769 | Psoriasis (vulgaris), strict definition | FING00001223 | 3.39e-03 |
| 8770 | Phospholipids to Total Lipids in Large VLDL percentage | GCST90498258 | 3.39e-03 |
| 8771 | Omega-3 fatty acid levels | GCST90502436 | 3.38e-03 |
| 8772 | Cholesteryl Esters to Total Lipids in Medium VLDL percentage | GCST90498944 | 3.38e-03 |
| 8773 | CXCL11/ITGB1BP2 ratio | GCST90314335 | 3.38e-03 |
| 8774 | CASP8/PRDX6 ratio | GCST90313655 | 3.38e-03 |
| 8775 | BLVRB/CA3 ratio | GCST90313523 | 3.36e-03 |
| 8776 | CPE levels | GCST90468841 | 3.36e-03 |
| 8777 | ATOX1/SNAP29 ratio | GCST90313374 | 3.35e-03 |
| 8778 | Triglycerides to Total Lipids in Very Large VLDL percentage | GCST90500692 | 3.35e-03 |
| 8779 | Gastric ulcer | GCST90018631 | 3.35e-03 |
| 8780 | Bone marrow fat fraction of lumbar vertebra 5 | GCST90652390 | 3.35e-03 |
| 8781 | CLEC1B/DKK1 ratio | GCST90314088 | 3.34e-03 |
| 8782 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502179 | 3.34e-03 |
| 8783 | CDKN1A/ENO2 ratio | GCST90313969 | 3.34e-03 |
| 8784 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 108) | GCST90320927 | 3.34e-03 |
| 8785 | Birth weight known - Yes - pounds and ounces | Early life factors | UKBB00000097 | 3.33e-03 |
| 8786 | RGMB/TNFRSF21 ratio | GCST90315772 | 3.32e-03 |
| 8787 | monocyte (absolute count, maximum, inv-norm transformed) | GCST90475499 | 3.32e-03 |
| 8788 | LEPR/NTRK2 ratio | GCST90315313 | 3.32e-03 |
| 8789 | Cancer of urinary organs (incl. kidney and bladder) (PheCode 189) | GCST90475593 | 3.32e-03 |
| 8790 | LPO levels | GCST90241730 | 3.32e-03 |
| 8791 | T1 FreeSurfer DK lh precuneus volume | GCST90385680 | 3.32e-03 |
| 8792 | VSIR levels | GCST90471053 | 3.31e-03 |
| 8793 | SERPINB1/TMSB10 ratio | GCST90315830 | 3.31e-03 |
| 8794 | Free cholesterol in very small VLDL (UKB data field 23521) | GCST90269618 | 3.31e-03 |
| 8795 | SKAP2 levels | GCST90470646 | 3.31e-03 |
| 8796 | Alcohol use disorder, ICD-based | FING00000052 | 3.31e-03 |
| 8797 | CEBPB/PXN ratio | GCST90314008 | 3.30e-03 |
| 8798 | LAT/PDGFA ratio | GCST90315285 | 3.30e-03 |
| 8799 | IL18BP/THBD ratio | GCST90315156 | 3.30e-03 |
| 8800 | Leg fat mass (left) | Impedance measures | UKBB00000389 | 3.30e-03 |
| 8801 | ADGRE5/NOTCH1 ratio | GCST90313181 | 3.30e-03 |
| 8802 | CXCL5/SPARC ratio | GCST90314355 | 3.29e-03 |
| 8803 | Current employment status - Doing unpaid or voluntary work | Employment | UKBB00000157 | 3.28e-03 |
| 8804 | CALCOCO1/TBC1D5 ratio | GCST90313610 | 3.28e-03 |
| 8805 | Saturated fatty acids to total fatty acids percentage | GCST90502207 | 3.28e-03 |
| 8806 | Octadecanedioylcarnitine (C18-DC) levels | GCST90199992 | 3.28e-03 |
| 8807 | Sphingomyelin_38:2_[M+H]1+ levels | GCST90060302 | 3.27e-03 |
| 8808 | Cheesecake liking | GCST90094730 | 3.27e-03 |
| 8809 | NXF1 levels | GCST90242149 | 3.26e-03 |
| 8810 | Enlarged prostate (Benign prostatic hyperplasia) | GCST90475261 | 3.26e-03 |
| 8811 | T1 FreeSurfer DK rh supramarginal volume | GCST90385787 | 3.26e-03 |
| 8812 | Salami liking | GCST90094825 | 3.25e-03 |
| 8813 | Cognitive function (baseline) | GCST90565836 | 3.25e-03 |
| 8814 | FABP4/SNCG ratio | GCST90314759 | 3.25e-03 |
| 8815 | Cholesterol in small LDL (UKB data field 23547) | GCST90269644 | 3.24e-03 |
| 8816 | HDL cholesterol | Blood biochemistry | UKBB00000306 | 3.24e-03 |
| 8817 | Ever taken cannabis | Cannabis use | UKBB00000224 | 3.23e-03 |
| 8818 | Cholesterol in Small LDL | GCST90499559 | 3.23e-03 |
| 8819 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T473 | ECGU000473 | 3.23e-03 |
| 8820 | OXT levels | GCST90470139 | 3.23e-03 |
| 8821 | Gamma-CEHC glucuronide levels | GCST90199941 | 3.23e-03 |
| 8822 | Left-hemisphere dorsal attention network to putamen white-matter structural connectivity | GCST90302703 | 3.23e-03 |
| 8823 | Cholesteryl esters in LDL (UKB data field 23417) | GCST90269514 | 3.22e-03 |
| 8824 | IGFBPL1 levels | GCST90469533 | 3.22e-03 |
| 8825 | PF4 levels | GCST90470211 | 3.21e-03 |
| 8826 | total cholesterol (mean, inv-norm transformed) | GCST90476424 | 3.21e-03 |
| 8827 | VAT1 levels | GCST90471029 | 3.21e-03 |
| 8828 | MSRA/P4HB ratio | GCST90315495 | 3.20e-03 |
| 8829 | CCN1/DNAJB1 ratio | GCST90313709 | 3.19e-03 |
| 8830 | Phenylacetate levels | GCST90199630 | 3.19e-03 |
| 8831 | FBLN2 levels | GCST90469193 | 3.19e-03 |
| 8832 | Free cholesterol in very small VLDL | GCST90500777 | 3.19e-03 |
| 8833 | DIABLO levels | GCST90468994 | 3.19e-03 |
| 8834 | Biological Grandparent (paternal): Coronary Artery / Coronary Heart Disease | GCST90475548 | 3.18e-03 |
| 8835 | Volume of right central nucleus | GCST90475024 | 3.17e-03 |
| 8836 | KHK levels | GCST90469675 | 3.17e-03 |
| 8837 | VASH1 levels | GCST90471026 | 3.17e-03 |
| 8838 | 5alpha-androstan-3beta,17beta-diol disulfate levels | GCST90199835 | 3.15e-03 |
| 8839 | TNFRSF11B levels | GCST90012002 | 3.15e-03 |
| 8840 | VLDL cholesterol levels | GCST90500189 | 3.15e-03 |
| 8841 | C2 levels | GCST90468497 | 3.15e-03 |
| 8842 | ICD10 O60: Preterm labor and delivery | GCST90454242 | 3.14e-03 |
| 8843 | IL18RAP levels | GCST90469566 | 3.14e-03 |
| 8844 | Non-small cell lung cancer, squamous, excluding all cancers (controls excluding all cancers) | FING00000877 | 3.14e-03 |
| 8845 | Concentration of small LDL particles (UKB data field 23544) | GCST90269641 | 3.13e-03 |
| 8846 | Diabetes diagnosed by doctor | Medical conditions | UKBB00000168 | 3.13e-03 |
| 8847 | CD300LG/TNFRSF1A ratio | GCST90313803 | 3.13e-03 |
| 8848 | Psoas tendinitis | FING00001221 | 3.13e-03 |
| 8849 | GM3 ganglioside (d18:1/24:0) levels | GCST90025340 | 3.12e-03 |
| 8850 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T56 | ECGA000056 | 3.12e-03 |
| 8851 | Sleep apnea | GCST90475257 | 3.11e-03 |
| 8852 | Mean bone marrow fat fraction of lumbar vertebrae 1-5 | GCST90652391 | 3.11e-03 |
| 8853 | Number of sexual partners in opposite-sex sexual behavior | GCST90026482 | 3.11e-03 |
| 8854 | Anaemias | FING00000082 | 3.11e-03 |
| 8855 | 3-amino-2-piperidone levels | GCST90200188 | 3.10e-03 |
| 8856 | Free cholesterol in small VLDL (UKB data field 23514) | GCST90269611 | 3.10e-03 |
| 8857 | Drinks usually with meals in current drinkers (yes and it varies vs no) (UKB data field 1618) | GCST90132925 | 3.10e-03 |
| 8858 | Cholesteryl Esters in HDL | GCST90497357 | 3.10e-03 |
| 8859 | Volume of right paralaminar nucleus | GCST90475051 | 3.09e-03 |
| 8860 | AXIN1/NFATC1 ratio | GCST90313415 | 3.09e-03 |
| 8861 | DAPP1 levels | GCST90468946 | 3.09e-03 |
| 8862 | Phospholipid levels in very small VLDL | GCST90132659 | 3.08e-03 |
| 8863 | Free Cholesterol to Total Lipids in Medium HDL percentage | GCST90498580 | 3.08e-03 |
| 8864 | Body mass index (BMI, mean, inv-normal transformed) | GCST90475156 | 3.08e-03 |
| 8865 | STK4 levels | GCST90470767 | 3.07e-03 |
| 8866 | Red cell distribution width variance | GCST90565705 | 3.06e-03 |
| 8867 | CSF3R levels | GCST90468885 | 3.06e-03 |
| 8868 | Pre-existing hypertension complicating pregnancy, childbirth and the puerperium | FING00001203 | 3.06e-03 |
| 8869 | SNAP29/VEGFC ratio | GCST90315862 | 3.05e-03 |
| 8870 | Principal component-derived dietary pattern 10 | GCST90133015 | 3.05e-03 |
| 8871 | DTI TBSS L2 Superior fronto-occipital fasciculus L | GCST90384519 | 3.05e-03 |
| 8872 | T1 FreeSurfer a2009s lh S central thickness | GCST90384786 | 3.04e-03 |
| 8873 | Breast cancer (triple negative or BRCA1-positive) | GCST010100 | 3.02e-03 |
| 8874 | PLXNA4 levels | GCST90470265 | 3.02e-03 |
| 8875 | N-acetylalanine levels | GCST90200303 | 3.01e-03 |
| 8876 | IDP dMRI TBSS L1 Posterior limb of internal capsule L | GCST90004094 | 3.01e-03 |
| 8877 | Concentration of chylomicrons and extremely large VLDL particles (UKB data field 23481) | GCST90269578 | 3.00e-03 |
| 8878 | EIF4G1/FKBP5 ratio | GCST90314633 | 3.00e-03 |
| 8879 | Monocyte count | GCST004625 | 2.99e-03 |
| 8880 | SPINK5/SPINT1 ratio | GCST90315877 | 2.99e-03 |
| 8881 | Diseases of middle ear and mastoid | FING00000427 | 2.98e-03 |
| 8882 | Length of mobile phone use | Electronic device use | UKBB00000403 | 2.98e-03 |
| 8883 | MPHOSPH8/USP8 ratio | GCST90315479 | 2.98e-03 |
| 8884 | Remnant cholesterol (non-HDL, non-LDL -cholesterol) levels (UKB data field 23402) | GCST90269499 | 2.97e-03 |
| 8885 | ARHGAP1 levels | GCST90468352 | 2.97e-03 |
| 8886 | ADGRE5/VCAM1 ratio | GCST90313184 | 2.97e-03 |
| 8887 | GLOD4/HSPA1A ratio | GCST90314937 | 2.97e-03 |
| 8888 | NECTIN2/VSIR ratio | GCST90315533 | 2.96e-03 |
| 8889 | CLEC4G/NELL2 ratio | GCST90314122 | 2.96e-03 |
| 8890 | DAPK2 levels | GCST90468945 | 2.96e-03 |
| 8891 | Phospholipids in large VLDL | GCST90498243 | 2.96e-03 |
| 8892 | CALCOCO1/VPS53 ratio | GCST90313612 | 2.95e-03 |
| 8893 | TP53BP1 levels | GCST90470936 | 2.95e-03 |
| 8894 | HAO1 levels | GCST90469429 | 2.95e-03 |
| 8895 | Alcohol drinker status: current or former vs never (UKB data field 20117) | GCST90132923 | 2.95e-03 |
| 8896 | CTSZ levels | GCST90468918 | 2.94e-03 |
| 8897 | Polyunsaturated fatty acid levels | GCST90502142 | 2.94e-03 |
| 8898 | TNFRSF19 levels | GCST90088947 | 2.94e-03 |
| 8899 | Cholesterol in very large VLDL (UKB data field 23491) | GCST90269588 | 2.93e-03 |
| 8900 | 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (p-16:0/18:2) levels | GCST90200060 | 2.93e-03 |
| 8901 | SNAP25 levels | GCST90470691 | 2.93e-03 |
| 8902 | Cholesterol in IDL (UKB data field 23526) | GCST90269623 | 2.93e-03 |
| 8903 | Nap during day | Sleep | UKBB00000492 | 2.92e-03 |
| 8904 | BCL2L2 levels | GCST90422077 | 2.92e-03 |
| 8905 | Variation in diet | Diet | UKBB00000892 | 2.92e-03 |
| 8906 | Chronic diseases of tonsils and adenoids | FING00000283 | 2.92e-03 |
| 8907 | Triglyceride to HDL cholesterol ratio | GCST90295949 | 2.92e-03 |
| 8908 | T1 CAT volume R RightThalamus | GCST90384097 | 2.91e-03 |
| 8909 | Free Cholesterol in HDL | GCST90497381 | 2.91e-03 |
| 8910 | CXCL1 levels | GCST90468930 | 2.91e-03 |
| 8911 | CD84/VASH1 ratio | GCST90313920 | 2.91e-03 |
| 8912 | Leg fat mass (right) | Impedance measures | UKBB00000390 | 2.91e-03 |
| 8913 | Eustachian tube disorders (PheCode 381.2) | GCST90475904 | 2.90e-03 |
| 8914 | Total lipids in chylomicrons and extremely large VLDL (UKB data field 23482) | GCST90269579 | 2.89e-03 |
| 8915 | Cholesteryl Esters to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500956 | 2.89e-03 |
| 8916 | Triglycerides | GCST90018755 | 2.89e-03 |
| 8917 | CPM/PCSK9 ratio | GCST90314216 | 2.88e-03 |
| 8918 | BA-exvivo lh area BA3b | GCST90003210 | 2.88e-03 |
| 8919 | DIABLO/GRAP2 ratio | GCST90314466 | 2.88e-03 |
| 8920 | Malignant neoplasm of liver, primary (PheCode 155.1) | GCST90475569 | 2.87e-03 |
| 8921 | IDP dMRI TBSS L1 Cingulum cingulate gyrus R | GCST90004109 | 2.87e-03 |
| 8922 | Concentration of IDL particles | GCST90497614 | 2.87e-03 |
| 8923 | Hypo-osmolality and hyponatraemia | FING00000648 | 2.85e-03 |
| 8924 | Cholesteryl esters in IDL (UKB data field 23527) | GCST90269624 | 2.84e-03 |
| 8925 | CASP8/PPP3R1 ratio | GCST90313654 | 2.83e-03 |
| 8926 | Saturated fatty acids to total fatty acids percentage | GCST90502696 | 2.83e-03 |
| 8927 | Cervicalgia (PheCode 761) | GCST90476267 | 2.82e-03 |
| 8928 | AXIN1/GOPC ratio | GCST90313407 | 2.80e-03 |
| 8929 | TNFSF13 levels | GCST90470921 | 2.80e-03 |
| 8930 | VTA1 levels | GCST90471058 | 2.80e-03 |
| 8931 | Acetate levels (UKB data field 23475) | GCST90269572 | 2.80e-03 |
| 8932 | CHMP1A levels | GCST90468746 | 2.79e-03 |
| 8933 | Mean platelet volume during third trimester of pregnancy | GCST90302231 | 2.79e-03 |
| 8934 | Total lipids in IDL (UKB data field 23524) | GCST90269621 | 2.79e-03 |
| 8935 | GOLM2 levels | GCST90469376 | 2.79e-03 |
| 8936 | Microvirga abundance in stool | GCST90032479 | 2.79e-03 |
| 8937 | Left-hemisphere visual network to right-hemisphere control network white-matter structural connectivity | GCST90302660 | 2.79e-03 |
| 8938 | FYB1/PDGFB ratio | GCST90314912 | 2.78e-03 |
| 8939 | Concentration of large LDL particles | GCST90498029 | 2.78e-03 |
| 8940 | RARRES2/TFPI ratio | GCST90315760 | 2.78e-03 |
| 8941 | Other headache syndromes | FING00001055 | 2.78e-03 |
| 8942 | CRTAM/GZMA ratio | GCST90314275 | 2.77e-03 |
| 8943 | Frequency of drinking alcohol | Alcohol use | UKBB00000260 | 2.77e-03 |
| 8944 | Phospholipids in large VLDL (UKB data field 23497) | GCST90269594 | 2.74e-03 |
| 8945 | Immature reticulocyte fraction (UKB data field 30280) | GCST90468079 | 2.74e-03 |
| 8946 | Monocyte percentage | Blood count | UKBB00000480 | 2.74e-03 |
| 8947 | MMP8/TGFA ratio | GCST90315466 | 2.73e-03 |
| 8948 | T1 FreeSurfer a2009s lh G front sup thickness | GCST90384757 | 2.73e-03 |
| 8949 | White blood cell count | GCST90018758 | 2.73e-03 |
| 8950 | CEACAM8/VNN2 ratio | GCST90314005 | 2.73e-03 |
| 8951 | Bone marrow fat fraction of lumbar vertebra 2 | GCST90652387 | 2.73e-03 |
| 8952 | CTSF/NAAA ratio | GCST90314314 | 2.72e-03 |
| 8953 | F-highly palatable foods liking (derived food-liking factor) | GCST90094785 | 2.71e-03 |
| 8954 | LYPD3 levels | GCST90469828 | 2.71e-03 |
| 8955 | Enthesopathy (PheCode 726.1) | GCST90476239 | 2.71e-03 |
| 8956 | SCAMP3/STX4 ratio | GCST90315805 | 2.70e-03 |
| 8957 | Free Cholesterol to Total Lipids in Small HDL percentage | GCST90499436 | 2.69e-03 |
| 8958 | MAP4K5/TBCC ratio | GCST90315385 | 2.69e-03 |
| 8959 | Migraine (PheCode 340) | GCST90475837 | 2.68e-03 |
| 8960 | Average diameter for VLDL particles (UKB data field 23431) | GCST90269528 | 2.68e-03 |
| 8961 | CD164/NUDT5 ratio | GCST90313742 | 2.67e-03 |
| 8962 | Phosphoglycerides levels (UKB data field 23434) | GCST90269531 | 2.67e-03 |
| 8963 | Omega-3 fatty acids to total fatty acids percentage | GCST90502451 | 2.66e-03 |
| 8964 | HSPB1 levels | GCST90179317 | 2.65e-03 |
| 8965 | Medication use (adrenergics, inhalants) | GCST90018779 | 2.65e-03 |
| 8966 | SIGLEC8 levels | GCST90470636 | 2.65e-03 |
| 8967 | Cholesterol in large VLDL (UKB data field 23498) | GCST90269595 | 2.65e-03 |
| 8968 | Mild age-related type 2 diabetes | GCST90026416 | 2.64e-03 |
| 8969 | Other embolism and thrombosis | FING00001043 | 2.64e-03 |
| 8970 | CIAPIN1/PLA2G4A ratio | GCST90314065 | 2.63e-03 |
| 8971 | potassium (minimum, inv-norm transformed) | GCST90476310 | 2.63e-03 |
| 8972 | Other predominantly sexually transmitted diseases, not elsewhere classified | FING00001089 | 2.63e-03 |
| 8973 | Triglycerides in chylomicrons and extremely large VLDL (UKB data field 23487) | GCST90269584 | 2.62e-03 |
| 8974 | ENO2/TXNDC5 ratio | GCST90314671 | 2.61e-03 |
| 8975 | Juvenile arthritis (FINNGEN) | FING00000704 | 2.61e-03 |
| 8976 | ALDH1A1/RBKS ratio | GCST90313247 | 2.61e-03 |
| 8977 | B4GALT1/B4GAT1 ratio | GCST90313429 | 2.61e-03 |
| 8978 | Alcohol drinker status: current vs never (UKB data field 20117) | GCST90132924 | 2.60e-03 |
| 8979 | Total Lipids in HDL | GCST90497393 | 2.60e-03 |
| 8980 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T57 | ECGA000057 | 2.60e-03 |
| 8981 | IDP T1 FAST ROIs R cerebellum VIIb | GCST90002577 | 2.59e-03 |
| 8982 | Raynaud's syndrome | GCST90448187 | 2.59e-03 |
| 8983 | Concentration of large VLDL particles (UKB data field 23495) | GCST90269592 | 2.59e-03 |
| 8984 | Glucose levels | GCST90092819 | 2.58e-03 |
| 8985 | IL12B levels | GCST90469549 | 2.58e-03 |
| 8986 | SERPINB1/SERPINB6 ratio | GCST90315826 | 2.58e-03 |
| 8987 | Ulcerative proctitis | FING00001393 | 2.57e-03 |
| 8988 | Milky sweets liking | GCST90094802 | 2.57e-03 |
| 8989 | LILRA2 levels | GCST90469771 | 2.57e-03 |
| 8990 | ITGB5/S100A4 ratio | GCST90315233 | 2.57e-03 |
| 8991 | CD40LG/EREG ratio | GCST90313820 | 2.57e-03 |
| 8992 | Two-hour glucose | GCST90002227 | 2.57e-03 |
| 8993 | TNFSF14 levels | GCST90470922 | 2.57e-03 |
| 8994 | Left-hemisphere dorsal attention network to right-hemisphere somatomotor network white-matter structural connectivity | GCST90302695 | 2.56e-03 |
| 8995 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502153 | 2.56e-03 |
| 8996 | Free cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23582) | GCST90269679 | 2.55e-03 |
| 8997 | Fasciitis (PheCode 728.7) | GCST90476244 | 2.55e-03 |
| 8998 | B4GALT1/SPON2 ratio | GCST90313434 | 2.54e-03 |
| 8999 | CDC37 levels | GCST90468665 | 2.54e-03 |
| 9000 | RELT levels | GCST90470453 | 2.54e-03 |